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Abstract 
Gangliosides, sialic acid-containing glycosphingolipids, enhance platelet adhesion to collagen and consequent platelet activation. For 
example, gangliosides shed by neuroblastoma tumor cells (NBTG) added to a subthreshold (non-activating) concentration (1 /zg/ml) of 
collagen, cause platelet aggregation (59 _+ 10%) and ATP release (2.3 _+ 0.2 nmol) equivalent to that caused by 10/xg/ml collagen alone. 
Here we report further studies to characterize this effect. Platelet aggregation and ATP release were not induced by NBTG in combination 
with subthreshold concentrations of adenosine diphosphate, pinephrine, thrombin or arachidonic acid, suggesting that NBTG specifically 
influences collagen-mediated platelet activation. Maximal platelet aggregation and ATP release required extracellular magnesium and 
only a short (1 rain) preincubation with NBTG, suggesting a collagen receptor-mediated mechanism of this ganglioside activity. Since 
gangliosides interact with several integrin receptors, we determined whether NBTG influences a 2/3 I, a major integrin collagen receptor 
on platetets. Incubation of platelets with a monoclonal antibody directed against he a e chain (5E8) blocked the increase in platelet 
aggregation (9_+ 3% vs. 80 + 2%) and ATP release (< 0.2 vs. 2.5 _+ 0.1 nmol) induced by NBTG and 1 /zg/ml collagen. Incubation 
with an antibody to the non-integrin collagen receptor, CD36, or with an isotype control antibody did not abrogate the effect of NBTG. 
Finally, NBTG and its major component, GD2, enhanced a 2/3~-mediated platelet adhes~:.n to immobilized collagen in an antibody 
5E8-inhibitable manner. These findings implicate the a 2/31-collagen i teraction as a target of the effect of tumor-derived gangliosides. 
Keywords: Ganglioside: Platetet; Integrin: Adhesion 
1. Introduction 
Tumor metastasis is a complex process consisting of a 
series of steps including local tumor growth, invasion and 
release of tumor cells into the lymphatic or vascular 
system, their transport in the circulation and interaction 
with platelets and coagulation proteins, subsequent arrest 
at a distant site, migration into the tissue, and finally 
growth at the secondary site. This process is dependent on 
a number of cell-cell interactions including homotypic 
platelet interactions [1,2] in which enhanced platelet activa- 
tion may play an important role [3-7]. The mechanisms 
which underlie this enhanced platelet activation are not 
known [6]. However, certain tumor cells activate platelets 
in vitro [6], possibly by an action of membrane bound 
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sialic acid-containing complexes [8]. Gangliosides, sialic 
acid-containing glycosphingolipids found predominantly in
cell membranes are candidates for such activity. These 
molecules have a water-soluble carbohydrate head group 
and a lipophilic tail, are shed by tumor cells in substantial 
quantities, and enter the circulation [9-1 1] where they are 
transported in association with lipoproteins [12]. We postu- 
late that in the circulation, these molecules interact with 
host cells and modify their function in such a way as to 
promote tumor metastasis. 
We previously reported that circulating tumor-derived 
gangliosides interact with platelets to enhance collagen- 
mediated activation [13]. Pre-incubation of platelets with 
the tumor-derived gangliosides resulted in platelet aggrega- 
tion and ATP release following exposure to a sub-threshold 
(non-activating) concentration of collagen (i.e., the highest 
concentration of collagen that failed to induce > 10% 
platelet aggregation or > 0.2 nmol ATP release) [14]. In 
the present work, we further studied the role of these 
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gangliosides in the process of platelet activation and delin- 
eate one possible mechanism for this activity. The evi- 
dence suggests that tumor gangliosides sensitize, or prime, 
platelets for the activating effects of collagen through an 
effect on ~2/~1 integrin-mediated platelet activation. We 
propose that this activity, modulation of integrin function, 
may be one mechanism by which tumor-derived ganglio- 
sides enhance tumor progression, by augmenting cell-cell 
interactions and subsequent metastasis. 
2. Materials and methods 
Materials. To assess platelet aggregation and ATP re- 
lease, equine type I collagen from Chronolog Corp. 
(Havertown, PA) was used. Native collagen fibrils from 
equine tendons (Collagen reagent Horm, Hormon-Chemie, 
Munich, GMBH) were used to assess adhesion. Adenosine 
diphosphate, pinephrine, thrombin, arachidonic acid, as- 
pirin and RGDS peptide were obtained from Sigma (St. 
Louis, MO). The anti-c~ 2 monoclonal antibody 5E8 [15] 
was generously provided by Richard Bankert, the OKM5 
and OKM8 anti-CD36 antibodies [16] were a gift from 
Patricia Rao and the LA-N5 cells [17] were kindly pro- 
vided by Robert Seeger. 
Cell culture. LA-N5 human neuroblastoma cells were 
passaged without antibiotics in Leibowitz media supple- 
mented with 15% fetal serum (Gibco) and 2 mM L-gluta- 
mine. The cells were maintained at 37°C with 5% CO 2 and 
fed every other day. 
Ganglioside isolation. Total cellular gangliosides were 
isolated from LA-N5 neuroblastoma cells as previously 
described [18]. Briefly, the total lipids were extracted twice 
with l0 volumes of chloroform-methanol (1:1), the ex- 
tracts combined, dried under a stream of N 2, re-dissolved 
in a small volume of chloroform-methanol (1:1), and stored 
overnight at -20°C. Insoluble glycoproteins were re- 
moved by centrifugation (1000 X g, 4°C) and the super- 
natant dried under a stream of N~. The gangliosides were 
isolated by partitioning the dried total lipid extract in 
diisopropyl ether/1-butanol/water (6:4:5, v /v)  [19], fol- 
lowed by Sephedex G-50 gel exclusion chromatography to 
remove traces of salts and other low molecular weight 
contaminants and further purified by normal phase high- 
pressure liquid chromatography [18,20] using a Hibar RT 
LiChrosorb Sil00 NH 2 column (Merck, FRG). The total 
ganglioside fraction was collected, lyophilized and repuri- 
fled by gel exclusion chromatography to remove salts. 
Gangliosides were quantified as nmol lipid bound sialic 
acid (LBSA) by a modification of the method of Svenner- 
holm [21,22] and visualized by high performance thin-layer 
chromatography (HPTLC) [11,23]. Gangliosides were 
stained with resorcinol reagent and visualized as purple 
bands. 
Platelet isolation. Platelet donors had abstained from all 
medications for a minimum of seven days, had fasted 
overnight, and provided written informed consent. Platelets 
were isolated from three donors according to the methods 
of Mustard et al. [24]. Briefly, blood was drawn into a 
plastic syringe containing 35 units/ml preservative-free 
heparin. Additional anticoagulant [ACD-A(1:6)] was added 
and the platelet-rich plasma (PRP) isolated by centrifuga- 
tion (100 × g, 25 min at 22°C). For the aggregation and 
ATP release assays, the platelets were pelleted (3000 × g, 
15 min at 22°C), resuspended in 5 ml ACD-A, washed 
twice (3000 × g, 15 rain at 22°C), resuspended in citrated 
modified Tyrode's buffer (MTB) without Ca 2+ or Mg 2+ 
and washed two additional times prior to pooling for use. 
Platelets to study adhesion were prepared from platelet-rich 
plasma which was concentrated and gel-filtered in MTB 
without added Ca 2+ or Mg z+ over Sepharose 2B (Phar- 
macia, Piscataway, NJ) according to the methods of Coller 
et al. [25]. 
Platelet aggregation. Platelet aggregation was measured 
with a Model 600, P.I.C.A. TM Chronolog lumi-aggregome- 
ter (Chrono-Log Corp., Havertown, PA) [26]. Washed 
platelets were re-suspended at 10~/#1 in purified ganglio- 
sides dissolved in citrated MTB, and incubated for one 
hour (unless otherwise indicated) at 37°C with gentle 
mixing. Following this preincubation, the platelets were 
washed three times, re-suspended to a concentration of 
105/p,l in MTB containing 2 mmol/ l  each of CaCI 2 and 
MgCI 2. 225 /~1 of the platelet suspension was added to 
siliconized glass cuvettes containing silicon-coated stir 
bars, and incubated for 30 min (37°C). Agonists were 
added in a 25-/xl volume to achieve the indicated final 
concentrations. Aggregation was measured turbidometri- 
cally [27] as the change in light transmission compared to 
a reference cuvette containing only MTB and collagen. All 
experiments were performed in the absence of plasma. 
Neither fibrinogen nor other proteins were added to the 
reaction cuvette. Optimal and subthreshold concentrations 
of collagen were the lowest hat induced maximal aggrega- 
tion or ATP release and the highest hat failed to induce 
> 10% aggregation or > 0.2 nmol ATP release, respec- 
tively. In these experiments, the platelet enhancing activity 
of NBTG was identified by utilizing a non-activating, 
sub-threshold concentration f collagen [14] and determin- 
ing whether pre-exposure of platelets to gangliosides ren- 
dered them susceptible to activation by this subthreshold 
concentration f collagen. 
ATP release. ATP release was measured simultaneously 
in the aggregometer by the Chrono-Lume luciferace- 
luciferin assay [26,28] with the gain set to produce a 
full-scale deflection upon complete ATP release according 
to the manufacturer's instructions. The amount of ATP 
released (nmol/2.5 × 10 7 platelets/250 /xl) was quanti- 
fied by comparison of peak heights generated in experi- 
mental cuvettes compared to those generated by known 
standard amounts of ATP. 
Platelet adhesion assay. Platelet adhesion was deter- 
mined according to the methods of Ill et al. [29] and 
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Santoro et al. [30] as modified by Coller et al. [25]. Native 
collagen fibrils from equine tendons (Collagen reagent 
Horm, Hormon-Chemie, Munich, GMBH) were diluted 
with isotonic glucose (pH 2.7-2.9) to a concentration of 
33 /zg/ml. 100 /xl of this suspension was used to coat the 
wells of a polystyrene microtiter plate (Falcon 3915, Bec- 
ton-Dickenson) overnight at 22°C. The wells were aspi- 
rated and blocked with 100 /xl 0.5% bovine serum albu- 
men (BSA) solution for one hour at 22°C then washed 
three times. Gel-filtered platelets were adjusted to 105//xl 
in MTB containing 2 mmol/1 MgC12 and 100 /xl of the 
final platelet suspension added to each well. After a 60-rain 
incubation at 37°C with gentle mixing, the wells were 
vigorously washed six times with MTB to remove non-ad- 
herent platelets and aggregates. The presence of platelet 
aggregates was assessed by light microscopy before and 
after washing. While occasional oose, large aggregates 
were present after the 60-min incubation period, in all 
experiments, minimal or no aggregates were present at the 
conclusion of the assay. The adherent platelets were re- 
moved with trypsin (0.01%) and counted automatically 
(CoulterSTKR, Coulter Electronics, Heighleia, FL). 
3. Results 
Effect of gangliosides on collagen-initiated platelet acti- 
t:ation. The total cellular gangliosides i olated from human 
neuroblastoma tumor cells (NBTG) enhanced ATP release 
and platelet aggregation i response to non-activating con- 
centrations of collagen. This is shown in Fig. 1, in which 
the activity of 5 /xM NBTG is compared to that of 
gangliosides i olated from normal human brain (HBG) and 
normal human serum (HSG). No ATP release (< 0.2 
nmol) was observed when platelets were pre-incubated in
5 /xM HSG, while a significant increase in ATP release 
(1.3 + 0.1 nmol) was seen when platelets were preincu- 
bated in HBG (P < 0.05). Preincubation i NBTG caused 
the greatest ATP release (2.3 __+ 0.2) (P  < 0.01). Differ- 
ences in potency among NBTG, HBG, and HSG were also 
evident in their effects on platelet aggregation (59 _+ 10, 
31 _+ 12, and < 10% aggregation, respectively). These 
results confirm that circulating gangliosides of tumor pa- 
tients enhance platelet activation [13] and support our 
conclusion that ganglioside molecules derived from tumor 
cells may underlie the activity of the circulating ganglio- 
sides in patients with neuroblastoma. The results also 
suggest that the specific molecular structure of the ganglio- 
sides influences their ability to activate platelets. The most 
active gangliosides, NBTG, were therefore chosen to con- 
duct the experiments described below. 
Effect of NBTG on platelet actiL, ation initiated by other 
agonists. The first step in determining the mechanism of 
the effects of NBTG on platelet activation was to examine 
the possible selectivity of NBTG preincubation, by testing 
its effect on platelet activation by other agonists. Optimal 
and subthreshold concentrations of adenosine diphosphate 
(5 X 10 4 M and 5 X 10 -6 M), epinephrine (1 × 10 -4  M 
and 1 X 10 -6 M), thrombin (1 u/ml  and 0.1 u/ml)  and 
arachidonic acid (1000 ug/ml and 100 /xm/ml) were 
determined for washed platelets resuspended in MTB con- 
taining 2 mmol/1 each of MgCI 2 and CaCI 2. Next, prein- 
cubation of platelets with 5 /zM NBTG was studied. This 
causes maximal ATP release following exposure of the 
platelets to a subthreshold concentration of collagen [13]. 
However, this same NBTG concentration, together with 
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Fig. 1. Effect of gangliosides on platelet ATP release. Washed platelets were preincubated with 5.0 /xM NBTG, HBG or HSG for 30 min at 37°C with 
gentle rocking. Unbound gangliosides were removed by centrifugation and the platelets resuspended to a concentration of 105//xl in MTB containing 2
mmol/ l  CaCI_~ and MgC12. A subthreshold concentration of collagen (1 /xm/ml) was added and ATP release determined. Data shown are the 
means _+ S.E.M. of three experiments, each performed in duplicate. NBTG, neuroblastoma tumor gangliosides; HBG, human brain gangliosides; HSG, 
human serum gangliosides. 
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Fig. 2. Effect of NBTG on the lag phase of collagen-initiated platelet activation. Washed platelets were incubated with NBTG (0.05 /~M) for 30 rain at 
37°C, washed twice to remove unbound gangliosides, resuspended toa concentration of 105//zl in MTB with 2 mmol/l CaCI 2 and MgCI 2, and exposed 
to a subthreshold concentration of collagen (1 izg/ml) (solid squares). Tubes were rapidly chilled in an ice bath and ATP release determined at the 
indicated times after addition of collagen. Control platelets were incubated in buffer and then exposed to a standard (10 /xg/ml) (open circles) or 
subthreshold concentration of collagen (1 p~g/ml) (open squares). Data shown are the means + S.E.M. of three experiments, each performed in duplicate. 
sub-threshold concentrations of  adenosine diphosphate, 
epinephrine, arachidonic acid or thrombin caused no ATP  
release (Table 1) and is contrasted to ATP release by 
optimal concentrations of  each agonist. These results sug- 
gest that NBTG influences a specific, col lagen-dependent, 
process rather than some less specific process leading to 
platelet activation. 
Effect o f  NBTG on the lag phase o f  collagen acti~'ation. 
Col lagen-mediated platelet activation is characterized by 
an initial receptor- l igand interaction, a lag phase, and a 
terminal response phase which can be measured as platelet 
aggregation or secretion. Having shown that NBTG en- 
hances the terminal response phase of  ptatelet activation, 
we next determined the effects of  NBTG on the lag phase 
of platelet activation. NBTG- incubated platelets were ex- 
posed to col lagen for 15-120 s and ATP release measured 
(Fig. 2). Platelets preincubated in 0.05 /xM NBTG and 
exposed to 1 /xg /ml  col lagen (fi l led squares) release ATP 
in a manner indistinguishable from control platelets prein- 
cubated in MTB without gangliosides and exposed to a 
standard concentration (10 /xg /ml )  of col lagen (open cir- 
cles). In each case, ATP release did not occur until 45 s 
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Fig. 3. Effect of duration of ganglioside preincubation on collagen-initiated platelet activation. Washed platelets were incubated with 5.0 /zM NBTG for 
the time indicated, rapidly chilled (4°C), and unbound gangliosides removed by centrifugation. The platelets were resuspended to a concentration of 
105//zl in pre-warmed (37°C) MTB with 2 mmol/1 CaCI 2 and MgCI z. After a 30 min recovery period, a subthreshold concentration of collagen (I 
/xg/ml) was added and ATP release determined. Control platelets (open circles) were incubated in buffer and treated in parallel with NBTG-incubated 
platelets (solid squares). Each point represents he mean + S.E.M. of three separate xperiments, each performed in duplicate. 
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Table 1 
Effect of NBTG on platelet ATP release 
Platelet agonist Concentration ATP release 
(nmol/2.5 × 107/250 uL) a 
Control NBTG 
Collagen 10/tg/ml  1.4_+0.1 nt h 
1 /xg/ml  < 0.2 1.7___0.1 
ADP 5×t0  -4 M 1.6_+0.2 nt 
5×10 -6 M <0.2 0.2___0.1 
Epinephrine 1 × 10 -4 M 1.0+_0.1 nt 
1×10 6 M <0.2 <0.2 
Thrombin 1 u/ml 2.0_+0.1 nt 
0.1 u/ml < 0.2 < 0.2 
Arachidonic acid 1000/zg/ml 0.8_+0.1 nt 
100/xg/ml < 0.2 < 0.2 
a Results are the average of duplicate determinations and standard error 
from three separate xperiments. 
b not tested. 
after the addition of collagen, at which time the amount of 
ATP released was identical: (0.9 + 0.3 vs. 0.8 _ 0.3 nmol 
ATP) and greater than the amount released from control 
platelets preincubated in MTB without gangliosides and 
exposed to the sub-threshold concentration of collagen 
(open squares) ( < 0.2 nmol ATP). The preservation of the 
characteristic lag phase and the identical pattern of ATP 
release suggests that NBTG acts at a proximal step in the 
process of collagen-mediated platelet activation and fur- 
thermore does not appear to alter the normal physiological 
response of the platelet o collagen. 
Effect of the duration of NBTG preincubation on platelet 
actiuation. We next determined the time course of the 
priming effects of NBTG on platelet activation. In these 
experiments, platelets were preincubated with 5/zM NBTG 
at 37°C for 1 to 120 min, then rapidly chilled to 4°C, and 
unbound NBTG removed by centrifugation. The platelet 
pellet was resuspended and equilibrated for 30 min in 
pre-warmed (37°C) MTB with 2 mmol/l  CaC1 z and 2 
mmol/1 MgCI 2, and ATP release measured (Fig. 3). Mini- 
mal ATP release (< 0.3 nmol), was observed in control 
experiments when platelets were preincubated in MTB for 
up to 120 rain and then exposed to the sub-threshold 
concentration of collagen. In contrast, maximal activity 
(2.2 + 0.2 nmol ATP released) was observed following 
preincubation i NBTG regardless of how long (120 min) 
or short (1 min) the preincubation time. The rapid onset of 
the enhancing effect of NBTG suggests that the effect is 
independent of platelet metabolism and may reflect rapid 
ganglioside binding to platelets. Combined with the speci- 
ficity for collagen and the probable proximal site of action, 
the results suggested that NBTG might interact with and 
influence the binding of collagen to a surface collagen 
receptor. 
NBTG interacts with platelets by an a 2 ill-dependent 
mechanism. While a number of receptors for collagen have 
been proposed (reviewed in Ref. [31]), one of these, the 
integrin collagen receptor ce 2/3 t (very late antigen-2, 
VLA-2, GPIa/IIa), appears to be the predominant receptor 
mediating platelet-collagen interactions in the absence of 
plasma [25]. Since gangliosides are known to interact with 
several integrins [32-34], we studied the possibility that 
NBTG might exert its enhancing influence through an 
effect on the integrin collagen receptor, %/3j. In these 
experiments, we used an anti-c h monoclonal antibody, 
5E8, which blocks this receptor. In the absence of antibody 
(control), platelets preincubated with 5.0 /.tM NBTG and 
activated with a subthreshold concentration of collagen 
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anti-c~2 anti-CD36 IgG1 Buffer 
Fig. 4. Effect of blocking the integrin collagen receptor, 0/2 i l l ,  on  NBTG-enhanced platelet ATP release. Washed platelets were preincubated for 30 min 
with 5.0/zM NBTG at 37°C with gentle rocking. Then, unbound gangliosides were removed by centrifugation. An excess amount of monoclonal ntibody, 
5E8 anti-o/2 (10/xg/ml), OKM5 or OKM8 anti-CD36 monoclonal ntibody (40/zg/ml), or an equal amount of non-immune isotype control antibody was 
added. Following a 30-min incubation at 37°C, 2 mmol/1 MgC12 and collagen (1 /.Lg/ml) were added and ATP release determined. Data represent the 
means + S.E.M. of three separate xperiments, each performed in duplicate. 
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released 2.5 ___ 0.1 nmol ATP and demonstrated 80 _+ 7% 
aggregation, respectively (Fig. 4). In the presence of the 
o~ 2 blocking antibody, NBTG-enhanced ATP release and 
platelet aggregation were completely abrogated (Fig. 4). 
Incubation with OKM5 or OKM8 antibodies directed to 
CD36 (GP IV), which is a non-integrin collagen receptor 
on platelets [35], did not prevent NBTG-enhanced platelet 
activation (Fig. 4). Finally, no effect was observed when 
an irrelevant isotype control antibody was used (Fig. 4). 
These combined findings suggests that the effects of NBTG 
are specific for an ol 2/31-dependent mechanism leading to 
platelet activation. 
Role of divalent cations ions in the priming effect of 
gangliosides. Since magnesium ions play a critical role in 
the interaction of a 2 fll with collagen [30], we determined 
the requirement of NBTG for Mg 2+. In these experiments, 
physical aggregation, rather than ATP release was used as 
the end-point. This is because the luciferase assay used to 
quantify ATP cannot be performed in the absence of 
Mg 2+ ion. As shown in Table 2, only Mg 2+ (2 mmol/1) 
was necessary for the effect of NBTG. Ca 2+ alone (2 
mmol/1) was insufficient, while the effect of the combina- 
tion of Ca 2+ and Mg 2+ was not different from that of 
Mg 2+ alone. These findings that NBTG-enhanced, colla- 
gen-initiated platelet activation is Mg2+-dependent and 
does not require Ca 2+ are consistent with an a 2/31-media- 
ted effect [30]. 
NBTG augments platelet adhesion to collagen. Next, 
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Fig. 5. Effect of tumor-derived gangliosides on platelet adhesion to immobilized collagen. In panel A platelets were preincubated with NBTG (5 /xM) 
(solid bars), NBTG followed by anti-a 2 monoclonal antibody (10 /xg/ml) (shaded bars), buffer alone (open bars) or buffer followed by anti-o~ 2 
monoclonal antibody (hatched bars) and allowed to adhere to plastic wells coated with collagen (CL), fibrinogen (FB), fibronectin (FN), laminin (LM), or 
albumen (AB). Non-adherent platelets were removed by washing and the adherent platelet number determined. Results represent the mean + S.E.M. of 
three experiments, each performed in triplicate. In panel B the effects of GD2 (1 /zM) and anti-a 2 monoclonal antibody on platelet adhesion to 
immobilized collagen were examined. Results represent the mean _+ S.E.M. of four determinations in separate xperiments. 
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we determined how NBTG influences platelet adhesion to 
immobilized collagen. We found that NBTG enhanced the 
adhesion of platelets to collagen more than two-fold (146 
+ 25 × 103/mm 3 vs. 66 + 10 × 103/mm 3) (Fig. 5A). 
There was no effect of pre-exposure of platelets to 5 /~M 
NBTG upon platelet adhesion to fibrinogen, fibronectin, or 
laminin (130 + 20 vs. 122 + 15%, 70_  10 vs. 74 ___ 10% 
and 29 + 15 vs. 38 + 10%, respectively) nor was there any 
effect upon non-specific adhesion of platelets to albumen 
(25 _ 15 vs. 24 + 10%). Similar to the effects on aggrega- 
tion, the effect of NBTG on platelet adhesion was specific 
for collagen and could be blocked by 5E8 (43 + 20). 
In these same experiments, the effects of a single tumor 
ganglioside, Gin, on platelet adhesion were studied. Incu- 
bation of gel-filtered platelets with 1 /.,M GD2 enhanced 
adhesion (105 _+ 14 × 103/mm 3 vs. 38 ___ 9 X 103/ram3). 
The increase could be prevented by preincubation with 
anti-ce 2 monoclonal antibody 5E8 (41 + 20 × 103/mm 3) 
(Fig. 5B). Thus, NBTG and its major component, Go2, 
enhanced ce 2/31-mediated platelet adhesion to immobilized 
collagen in an antibody 5E8-inhibitable manner. These 
findings implicate the a2 fll-collag en interaction as a tar- 
get of the effect of tumor-derived gangliosides. 
Finally, we conducted additional experiments o deter- 
mine the contribution of platelet aggregation to the platelet 
adhesion, and particularly, the ganglioside nhancement of 
platelet adhesion observed in these experiments. Exposure 
of the platelets to 100 /zM aspirin for 30 min prior to 
incubation with GD2 did not abrogate the enhancement in 
adhesion (86 + 18 × 103/mm 3 vs. 105 + 14 × 103/mm 3) 
nor did incubation with 40 /xg/ml RGDS peptide (95 + 
14 × 103/ram 3) (Table 3). Performance of the assay at 
22°C without mixing diminished the stimulatory effects of 
GD2 compared to experiments done at 37°C with mixing 
(66 + l l × 103/mm 3 vs. 105 + 14 × 103/ram3). Despite 
this reduction, the effect of GD2 under these experimental 
conditions (22°C without mixing) was still three-fold 
greater than control (29 + 8 × 103/mm3). These experi- 
ments suggest hat neither arachidonic acid formation or 
cqzb f13 (glycoprotein IIb/IIIa) occupancy plays a role in 
Table 2 
Divalent cation 
gation 
requirements for NBTG-enhanced collagen platelet aggre- 
NBTG Magnesium Calcium % aggregation a 
(5.0/xM) (2 mmol/ l )  (2 mmol/ l )  
+ - - <10 
- - - <10 
+ + - 75 _+ 14 
- + - <10 
+ - + <10 
- - + <10 
+ + + 68_+ 10 
- + + <10 
Average of duplicate determinations and standard error from three 
separate xperiments. 
Table 3 
Effects of Go2 ganglioside on platelet adhesion to collagen under condi- 
tions in which platelet aggregation is prevented 
Experimental condition Platelet adhesion ~ 
Go2 Buffer 
Control 105 + 14 38 -+ 9 
Conditions inhibiting aggregation 
Asprin (100/xM) 86+ 18 42__ 13 
22°C, no mixing 66+ I 1 29_+8 
RGDS (40/xg/ml)  95 + 14 32_+ 11 
number adherent platelets × 103/mm ~. 
ganglioside-enhanced platelet activation in response to col- 
lagen. Furthermore, they confirm that the interaction of 
gel-filtered platelets with an immobilized fibrillar collagen 
substrate in the presence of Mg 2+ ions is due primarily to 
platelet adhesion and that secondary aggregation plays, at 
best, a minor role in this interaction. Together, these 
results (Table 3) confirm that the significant enhancing 
effect of the neuroblastoma tumor-derived ganglioside GD2 
is on platelet adhesion, not platelet aggregation. 
4. Discussion 
Gangliosides, shed from the surface of tumor cells, 
enhance tumor progression [10,11]. One mechanism by 
which these acidic glycosphingolipids may accomplish this 
is by interacting with and modulating the immunologic 
activity of host immunocytes including lymphocytes [36], 
monocytes [37], and NK cells [38]. Another mechanism by 
which shed tumor gangliosides may enhance tumor pro- 
gression and tumor metastasis is by enhancing platelet 
activation. Many steps in the metastic cascade involve 
changes in the ability of cells to adhere to each other, or to 
extracellular matrix proteins. Here we show that ganglio- 
sides shed by neuroblastoma tumor cells influence oz 2/31 
integrin-mediated platelet activation in response to low 
(normally inactive) concentrations of collagen. This effect 
is rapid, Mg2+-dependent, and specific for collagen. We 
suggest hat this interaction of tumor-derived gangliosides 
with integrins may occur not only on platelets but also on 
other cells including host endothelial cells [39], and thereby 
promote tumor cell adhesion in the vascular system and 
contribute to the establishment of metastatic foci [40]. 
Platelet activation is thought to be an integral step in the 
complex, multi-step cascade of events which occur during 
metastasis [3-7]. The association of tumor cells with 
platelets is well described in animal models of metastasis 
[41] and certain tumor cells can activate platelets in vitro 
[42,43]. However, the mechanism by which this associa- 
tion occurs is not known. It is known that an initial 
extracellular receptor-ligand interaction leads to a series of 
intracellular receptor-coupled vents which culminate in a 
cellular response [44-46]. When a sufficient number of 
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a2/31 receptors on the surface of circulating platelets 
interact with collagen in the subendothelial matrix, a cas- 
cade of intracellular events are initiated which amplify the 
initial signal. They lead to Ca 2+ influx and activation of 
protein kinase C. In turn, a multitude of cellular esponses, 
including release of adenine nucleotides and other compo- 
nents of platelet granules, platelet adhesion, and aggrega- 
tion [44]. 
Gangliosides interact with a number of cell surface 
receptors, including integrin receptors [32-34,47-49]. An 
initial demonstration that gangliosides can alter receptor 
function was provided by Bremer and Hakomori [50]. 
They showed that GM3 ganglioside inhibited cell growth 
by interacting with the cell surface receptors for platelet- 
derived growth factor and epidermal growth factor [50]. 
Neurite outgrowth and spreading [51], neuroblastoma cell 
adhesion [47] and germinal cell adhesion [52], all cell 
surface receptor-mediated processes, have subsequently 
been shown to be influenced by gangliosides, as is inter- 
nalization of the CD4 epitope on T-lymphocytes [53]. 
Similarly, platelet adhesion is influenced by gangliosides 
[54,55]. Complex gangliosides inhibit the adhesion of 
thrombin-activated platelets to the ail b /33 substrates, fi- 
bronectin, fibrinogen and von Wiilebrand factor [55]. Inter- 
actions between specific gangliosides and integrin 
molecules are also known. For example, monoclonal anti- 
bodies to the oligosaccharide portion of GD2 or  GD3 inhibit 
melanoma cell attachment and spreading [32]. Ganglio- 
sides colocalize with the integrin vitronectin receptor, 
cGfl 3, which in the presence of ganglioside and Ca 2+ 
demonstrates enhanced interaction with vitronectin. Re- 
cently, it was also shown that depletion of complex gan- 
gliosides results in a reduction in tumor cell adhesion to 
vitronectin, and a decrease in affinity of a v/33 for vit- 
ronectin, while supplementation with exogenous ganglio- 
sides restored the ability of the cells to adhere to vit- 
ronectin and enhanced the affinity of c G/33 for vitronectin 
[49]. Another example of ganglioside modulation of inte- 
grin function is the enhancement by GM3 of the interaction 
between the integrin fibronectin receptor, a 5/3j, and fi- 
bronectin [34]. 
The results of these experiments demonstrating enhanc- 
ing effects of pathologic tumor gangliosides on collagen- 
mediated platelet activation (Fig. 1 and Table 1), abroga- 
tion of this enhancing effect in the presence of anti-or 2
monoclonal antibody (Fig. 4), those defining a requirement 
for Mg 2+ ion (Table 2), and finally enhancement of 
platelet adhesion to immobilized collagen and abrogation 
of this enhancing effect in the presence of anti-ce 2 mono- 
clonal antibody (Fig. 5) provide several ines of evidence 
supporting the hypothesis that tumor gangliosides influ- 
ence a 2/31-mediated platelet activation. The mechanism 
L "2  
Fig. 6. Proposed schema of the influence of ganglioside shedding upon platelet activation and tumor metastasis. Tumor cells induce endothelial cell 
retraction (1A). Gangliosides are shed into the circulation from tumor cells (IB) and interact with resting platelets to prime them for subsequent activation 
[2]. The primed platelets may be activated by low, subthreshold concentrations of collagen present on intact blood vessels or as a result of tumor cell 
induced endothelial cell retraction [3]. Formation of platelet-endothelial ce l-tumor cell aggregate promotes tumor metastasis. 
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by which pathologic, tumor-derived gangliosides alter inte- 
grin function [32,49,56], and more specifically, platelet 
a 2/31 activity, is not known. What is known is that GM3 
comprises 92% of total cellular gangliosides in the platelet 
[57], is the major ganglioside in the platelet membrane, 
and is highly enriched in the platelet dense granule mem- 
brane [58]. Other gangliosides, including GM2 [59] and 
complex polysialogangliosides are present in the platelet 
membranes, but comprise only a minor fraction (< 2%) of 
the total and are absent from the dense granules [58]. 
NBTG is composed of two major gangliosides - GD2 and 
GM2 and a small amount of GTIb; HBG is composed of 
over 20 different gangliosides with GMI, GDI a and GvI b 
the major components. Finally, the major components of 
HSG are GM3 (which is absent in NBTG and a very minor 
component of HBG), G m, and Gma. Since qualitative or 
quantitative changes in gangliosides present in the platelet 
microenvironment have dramatic effects on platelet activ- 
ity [55], incubation of platelets in NBTG or HBG may be 
introducing complex ganglioside molecules that are either 
absent or present only in very low concentrations in the 
platelet membrane. In turn, these complex ganglioside 
molecules may alter integrin-ligand affinity directly through 
interactions with a 2 fl~ on the platelet surface or indirectly 
by influencing membrane fluidity and integrin clustering. 
Alternatively, their effects may be due to modulation of 
post-receptor signaling. With respect o the data presented 
here, we have two explanations for our observation that 
platelet adhesion is increased 2.2-fold by NBTG while 
aggregation is increased greater than 6-fold. First, NBTG 
may also influence downstream steps in the signal trans- 
duction pathway. Secondly, the difference in the magni- 
tude of the effect of NBTG on adhesion and aggregation 
could simply be due to physiologic amplification which 
occurs following the initial receptor-ligand interaction 
which ultimately leads to platelet aggregation. The mecha- 
nism(s) by which pathologic tumor-derived gangliosides 
affect a2 fl~-mediated platelet activation (e.g., modulation 
of affinity and/or clustering and/or signal transduction) is 
under investigation. 
Our data together with those of others begin to give a 
picture of how tumor gangliosides may influence the pro- 
cesses of integrin activation, cell adhesion, and metastasis. 
Schematically (Fig. 6): the intact endothelium normally 
prevents contact between platelets and collagen in the 
subendothelial matrix, but tumor cells induce endothelial 
cell retraction [60], exposing small amounts of collagen. 
Unless large areas of subendothelial matrix are exposed, 
however, this amount of collagen is insufficient in itself to 
cause platelet activation. But, tumor cells shed ganglio- 
sides [9-11] (Fig. 6, step 1B) which, we propose, can 
interact with circulating, resting platelets in vivo [13]. So, 
whereas in the physiological situation there are no tumor 
cells in the circulation and therefore neither 'exposed' 
collagen nor circulating tumor-derived gangliosides, when 
a tumor is present, platelets may be exposed to and bind 
tumor gangliosides. When platelets carrying such bound 
tumor gangliosides encounter 'insufficient' amounts of 
exposed collagen, they become acuvated, release ATP, 
aggregate, and adhere to collagen (Fig. 6). In turn, these 
tumor ganglioside-exposed platelets may promote the in- 
teraction of tumor cells with endothelial cells [40], a step 
in tumor metastasis. In conclusion, the findings that NBTG 
enhance a2/31-mediated platelet activation, combined with 
the observations by others that gangliosides modulate the 
activity of integrins, support he hypothesis that by enhanc- 
ing cell adhesion, tumor gangliosides contribute to the 
process of tumor cell metastasis. 
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